期刊
TRANSPLANT INTERNATIONAL
卷 26, 期 9, 页码 867-878出版社
WILEY
DOI: 10.1111/tri.12132
关键词
immunomodulation; living-related kidney transplantation; mesenchymal stromal cells; pretransplant cell infusion
资金
- Fondazione ART per la Ricerca sui Trapianti (Milan, Italy)
- Associazione Italiana Ricerca sul Cancro (AIRC) 5 per mille
- Piano Regionale Sangue-Lombardia
Bone marrow-derived mesenchymal stromal cells (MSC) have emerged as useful cell population for immunomodulation therapy in transplantation. Moving this concept towards clinical application, however, should be critically assessed by a tailor-made step-wise approach. Here, we report results of the second step of the multistep MSC-based clinical protocol in kidney transplantation. We examined in two living-related kidney transplant recipients whether: (i) pre-transplant (DAY-1) infusion of autologous MSC protected from the development of acute graft dysfunction previously reported in patients given MSC post-transplant, (ii) avoiding basiliximab in the induction regimen improved the MSC-induced Treg expansion previously reported with therapy including this anti-CD25-antibody. In patient 3, MSC treatment was uneventful and graft function remained normal during 1year follow-up. In patient 4, acute cellular rejection occurred 2 weeks post-transplant. Both patients had excellent graft function at the last observation. Circulating memory CD8+ T cells and donor-specific CD8+ T-cell cytolytic response were reduced in MSC-treated patients, not in transplant controls not given MSC. CD4+FoxP3+Treg expansion was comparable in MSC-treated patients with or without basiliximab induction. Thus, pre-transplant MSC no longer negatively affect kidney graft at least to the point of impairing graft function, and maintained MSC-immunomodulatory properties. Induction therapy without basiliximab does not offer any advantage on CD4+FoxP3+Treg expansion (ClinicalTrials.gov number: NCT 00752479).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据